Newtyn Management, LLC Aligos Therapeutics, Inc. Transaction History

Newtyn Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $1.07 $168,249 - $514,362	-480,713 Reduced 40.06%	719,287 $251,000
Q1 2024 May 15, 2024	SELL	$0.64 - $1.13 $35,200 - $62,149	-55,000 Reduced 4.38%	1,200,000 $1.18 Million
Q4 2023 Feb 14, 2024	BUY	$0.56 - $0.8 $187,600 - $268,000	335,000 Added 36.41%	1,255,000 $828,000
Q3 2023 Nov 14, 2023	BUY	$0.71 - $1.06 $14,200 - $21,200	20,000 Added 2.22%	920,000 $690,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $108,100 - $165,186	-121,461 Reduced 11.89%	900,000 $873,000
Q1 2023 May 15, 2023	SELL	$0.87 - $2.11 $416,328 - $1.01 Million	-478,539 Reduced 31.9%	1,021,461 $888,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $28.0 $445,000 - $14 Million	500,000 Added 50.0%	1,500,000 $1.43 Million
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $40,186 - $1.04 Million	37,912 Added 3.94%	1,000,000 $1.1 Million
Q2 2022 Aug 15, 2022	BUY	$1.04 - $2.14 $1 Million - $2.06 Million	962,088 New	962,088 $1.16 Million

37.7M

1.4K

300

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Newtyn Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Newtyn Management, LLC with notifications on news.